Literature DB >> 27587277

Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice.

Joseph L Izzo1, Yan Jia2, Dion H Zappe2.   

Abstract

The effects of race and age on 24-hour mean ambulatory systolic blood pressure (maSBP) responses to sequential 4-week periods of angiotensin receptor blocker therapy (valsartan [VAL] 160 mg/d then 320 mg/d and combination VAL/hydrochlorothiazide [HCTZ] 320/12.5 mg/d) were compared in 304 patients with stage 1 or 2 hypertension. There were lesser blood pressure (BP) responses from baseline with VAL monotherapy in black than Caucasian patients (-2.9 and -4.0 mm Hg vs -8.2 and -9.3 mm Hg, respectively; P<.001 each) but VAL/HCTZ BP responses were similar in both groups (-12 vs -15 mm Hg). Participants 65 years and older had lower BP responses with VAL 160 mg/d and 320 mg/d than those younger than 65 years (-2.8 and -4.5 mm Hg vs -6.5 and -7.5 mm Hg, respectively; P<.001) but similar responses to VAL/HCTZ (-14 vs -17 mm Hg). No BP response differences were found between those older than and those younger than 55 years. The authors conclude that: (1) adding low-dose HCTZ (12.5 mg daily) to VAL is more effective than VAL titration, irrespective of age or race, (2) VAL BP efficacy is lower in blacks than Caucasians, and (3) ARB responses are diminished in patients older than 65 years. Guidelines for stage 1 or 2 hypertension that suggest age 55 should determine initial monotherapy choice (eg, ARB vs thiazide diuretic) or that fail to recommend initial ARB-thiazide combination therapy should be reconsidered. ©2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27587277      PMCID: PMC8031356          DOI: 10.1111/jch.12891

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  27 in total

1.  Antihypertensive response to thiazide diuretic or angiotensin receptor blocker in elderly hypertensives is not influenced by pretreatment plasma renin activity.

Authors:  Howard S Weintraub; Daniel A Duprez; William C Cushman; Dion H Zappe; Das Purkayastha; Rita Samuel; Joseph L Izzo
Journal:  Cardiovasc Drugs Ther       Date:  2012-04       Impact factor: 3.727

2.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

3.  Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension.

Authors:  L C Rump; X Girerd; L Sellin; J Stegbauer
Journal:  J Hum Hypertens       Date:  2010-11-25       Impact factor: 3.012

4.  A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial.

Authors:  Ross D Feldman; Guang Y Zou; Margaret K Vandervoort; Cindy J Wong; Sigrid A E Nelson; Brian G Feagan
Journal:  Hypertension       Date:  2009-02-23       Impact factor: 10.190

5.  Ambulatory blood pressure and mortality: a population-based study.

Authors:  Tine Willum Hansen; Jørgen Jeppesen; Susanne Rasmussen; Hans Ibsen; Christian Torp-Pedersen
Journal:  Hypertension       Date:  2005-03-07       Impact factor: 10.190

6.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

7.  Evaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertension.

Authors:  Matthew R Weir; Nora Crikelair; Drew Levy; Ricardo Rocha; Venkatram Kuturu; Robert Glazer
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-02       Impact factor: 3.738

8.  Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study.

Authors:  Joseph L Izzo; Joel M Neutel; Tonous Silfani; Robert Dubiel; Findlay Walker
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

9.  Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker.

Authors:  Joseph L Izzo; Joel M Neutel; Tonous Silfani; Robert Dubiel; Findlay Walker
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-01       Impact factor: 3.738

10.  Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice.

Authors:  Joseph L Izzo; Yan Jia; Dion H Zappe
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-09-01       Impact factor: 3.738

View more
  4 in total

1.  Blood pressure response to metoprolol and chlorthalidone in European and African Americans with hypertension.

Authors:  Mai Mehanna; Yan Gong; Caitrin W McDonough; Amber L Beitelshees; John G Gums; Arlene B Chapman; Gary L Schwartz; Julie A Johnson; Stephen T Turner; Rhonda M Cooper-DeHoff
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-09-21       Impact factor: 3.738

Review 2.  Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations - A review.

Authors:  A A L Ajayi; O E Ajayi
Journal:  Int J Cardiol Cardiovasc Risk Prev       Date:  2021-10-28

3.  Influence of Age and Race on 24-Hour Ambulatory Blood Pressure Responses to Valsartan, Hydrochlorothiazide, and Their Combination: Implications for Clinical Practice.

Authors:  Joseph L Izzo; Yan Jia; Dion H Zappe
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-09-01       Impact factor: 3.738

4.  Association between serum 25-hydroxyvitamin D and the effects of Angiotensin II receptor blocker on renal function among African Americans: A post hoc analysis of a randomized placebo-controlled trial.

Authors:  Li Chen; Haidong Zhu; Gregory A Harshfield; Ying Huang; Yanbin Dong
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-18       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.